OV‘s second drug candidate in the clinic – First Multiple Myeloma patient in study with APO010, an Immuno-Oncology drug
Hoersholm, Denmark, May 31th, 2017 – Oncology Venture Sweden AB (OV:ST) today announced that the first patient has entered the APO010 Phase 1/2 study for Multiple Myeloma (MM). APO010 is a first-in-class FAS-ligand anticancer product in immuno-oncology (“IO”). The DRP™ (Drug Response Predictor) Screening for sensitive patients with MM at four centers has been ongoing and >50 patients have already consented to have their tumor tissue DRP analyzed. In total 150 evaluable patients, will be screened using OV’s DRP™ with the aim to identify those Multiple Myeloma patients with the highest